Population Pharmacokinetic Modeling to Optimize the Dosage of the Piperacillin / Tazobactam Combination in Patients With Sepsis in Intensive Care

NCT ID: NCT03748095

Last Updated: 2023-01-26

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 90 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2019-03-12
• Study Completion Date: 2024-06-15

Brief Summary

Population pharmacokinetic modeling mathematically describes the pharmacokinetics of a drug and the variables likely to influence it in a "typical" patient population. We propose to model a Bayesian estimator, taking into account the individual factors that influence exposure to the piperacillin / tazobactam combination in a target population of sepsis, to allow for early assessment of serum Piperacillin / Tazobactam concentration profiles. optimization of dosing regimens. Indeed, pharmacokinetic tools of this type are already regularly successfully applied for other classes of antibiotics or immunosuppressants whose therapeutic index is narrow. They reduce the toxic risk and optimize the effectiveness of these treatments.

Conditions

Resuscitation Patients With Sepsis

Study Design

• Observational Model Type: OTHER
• Study Time Perspective: PROSPECTIVE

Interventions

pipéracilline/tazobactam

There is not intervention description

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Major patient (age ≥18 years) male or female.
• Patient hospitalized in intensive care for sepsis, involving (i) a suspected or proven infection; (ii) a systemic inflammatory response; (iii) dysfunction of at least one organ, according to the international consensus "sepsis-3".
• Patient with an arterial catheter that can be used for blood sampling by the time the first dose of piperacillin / tazobactam is administered.
• Patient for whom treatment with piperacillin / tazobactam, alone or in combination with another antibiotic, is prescribed according to the following modalities (drug SPC): scheduled antibiotic treatment for at least 48 hours in IV infusion of 4 g of piperacillin and 0.5 g tazobactam over 3 hours, every 6 hours or every 8 hours.
• Patient affiliated to a social security scheme.
• Patient informed and given his non-opposition. If the patient is unable to do so (emergency situations) the non-opposition will be obtained from the patient's representative.

Exclusion Criteria

• Treatment with piperacillin and / or tazobactam within 7 days prior to evaluation.
• Patient with a history of allergy to penicillins or β-lactams.
• Kidney function of Kdigo score = 3 (3 times baseline plasma creatinine or plasma creatinine ≥ 354μmol / L or extra-renal clearance, or diuresis <0.3ml / kg / h for ≥ 24h or anuria for ≥ 12h) to not include patients at very high risk of extra-renal clearance within 48 hours.
• Hypersensitivity to the active substances, to any other antibacterial agent of the penicillin class or to any of the excipients.
• History of severe allergic reaction to any other β-lactam.
• Patient being treated with extrarenal treatment.
• Patient being treated with extracorporeal circulation (ECMO).
• Hepatic insufficiency patient with Child C. cirrhosis.
• Patient who refused to participate or refused participation by the representative.
• Person deprived of liberty by an administrative or judicial decision.
• Person under tutorship or curatorship.
• Pregnant or nursing woman.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital, Rouen

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CHU de Rouen

Rouen, , France

Site Status: RECRUITING

Countries

France

Facility Contacts

Lamoureux Fabien

Role: primary

Fabien.Lamoureux@chu-rouen.fr

0232886643

Other Identifiers

2017/384/HP

Identifier Type: REGISTRY

Identifier Source: secondary_id

2018-A02681-54

Identifier Type: -

Identifier Source: org_study_id